Specifically the fund will focus in the areas of biotechnology - the platform to reverse the "innovation deficit" in the pharmaceutical industry.
Specific investment criteria:
Bear Stearns Health Innoventures generally prefers to be the lead investor
© 2001-08 JPMorgan Chase & Co.